Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

William J. Taylor, Dafna D. Gladman, Philip Helliwell et al. · Arthritis & Rheumatism · 2006 · 3.7K citations

Medicine, Biostatistics, Clinical Sciences +16

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Dermatology, Immunology +14

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Life Sciences, Immunology, Pharmacotherapy +17

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Laure Gossec, Josef S Smolen, Sofía Ramiro et al. · Annals of the Rheumatic Diseases · 2016 · 913 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin et al. · Arthritis & Rheumatism · 2005 · 905 citations

Medicine, Pharmacology, Pharmacotherapy +15